BLGO BioLargo

BioLargo CEO Interviewed at The Wall Street Resource

BioLargo CEO Interviewed at The Wall Street Resource

Westminster, CA, Nov. 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioLargo (OTCQB: BLGO), developer of sustainable technologies and full-service environmental engineering, announced today that its President & CEO Dennis P. Calvert was interviewed by The Wall Street Resource, a platform for microcap company news and due diligence. The interview can be accessed here: .

Mr. Calvert’s interview highlighted several of BioLargo’s innovative clean tech products and services. In particular, Mr. Calvert gave an update on the development of the company’s new water treatment technology designed to address per- and poly-fluoroalkyl substances (PFAS), a class of water contaminants of growing concern in the US.

The interview with Mr. Calvert was published at 2:00 p.m. PST on November 13, 2019.  The interview webcast is free of cost to all listeners and available at . In addition, the interview will be available for replay.

About Biolargo (BLGO) 

BioLargo invents, patents, and develops innovative platform technologies for three markets: 1) advanced water and wastewater treatment, 2) industrial odor and VOC control, and 3) advanced wound care products. With a wide array of issued patents, an extensive R&D talent pool, and a full-service engineering team, the company maintains a robust pipeline of products from inception through maturity.  BioLargo monetizes its technology assets with the goal of maximizing both impact and shareholder value, using licensing, strategic partnership, and direct-to-market strategies. 

About The Wall Street Resource

The Wall Street Resource.com is a platform for microcap discovery and due diligence. It's your resource for webcast interviews of CEOs and executives. For more information, please visit: 

Safe Harbor Act

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Contact Information

Dennis P. Calvert, President & CEO of BioLargo, Inc. 

888-400-2863

EN
13/11/2019

Underlying

BLGOBioLargo

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioLargo

Sean Conroy
  • Sean Conroy
BLGO BIOLARGO

BioLargo - Firing on all cylinders

BioLargo reported $666,000 in total Q320 sales (+24.7% y-o-y), a new record, a $1.9m operating loss (flat year-on-year) and a $2.39m net loss (from $3.89m in Q319). It had $356,000 in Q320 sales from ONM Environmental, down 10% from Q319, but the division recovered significantly since the start of the pandemic (up 19% from Q120). Sequentially, companywide revenue growth was up 56% over Q220, a strong bounce back from COVID-19 disruptions, and total sales are up 15% for 9M20 to $1.52m. BioLargo a...

12/17/20 December 17, 2020 1 EN
Sean Conroy
  • Sean Conroy
BLGO BIOLARGO

BioLargo - Clyraguard to be a major growth driver

BioLargo stated that it expects Clyra Medical (of which it owns a 48% interest) and its Clyraguard product to be a major driver of growth in the coming periods. Clyra Medical signed an agreement with a major national distributor in July, with the first substantial sales to occur in Q320. Clyra Medical reported a small revenue ($21,000) for Q220, reflecting one week of sales from a previous test marketing run.

08/27/20 August 27, 2020 2 EN
 PRESS RELEASE
Free
BLGO BIOLARGO

Dennis P. Calvert, President & CEO of BioLargo, Inc. Provides Key Upda...

Dennis P. Calvert, President & CEO of BioLargo, Inc. Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com AUSTIN, Texas, June 08, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and BioLargo, Inc. (OTCQB:BLGO)(“the Company”), developer of sustainable technologies and a full-service environmental engineering company, today announced that a new audio interview with the Company is now available. The interview featuring an overview of BLGO’s current news and moves can be heard at . Dennis P. Calvert, President & CEO of BioLargo, discussed the Company’s bu...

June 8, 2020 1 EN
Sean Conroy
  • Sean Conroy
BLGO BIOLARGO

BioLargo - Clyra launches Clyraguard

Clyra Medical, BioLargo’s partially owned (36%) subsidiary, recently announced that it registered with the FDA and launched Clyraguard, a disinfectant marketed for the treatment of non-critical surfaces such as personal protective equipment (PPE) that is non-irritating to skin. Concurrent with this BioLargo announced the results of two studies that showed Clyraguard and the company’s environmental product CupriDyne could both fully inactivate COVID-19.

05/26/20 May 26, 2020 2 EN
Sean Conroy
  • Sean Conroy
BLGO BIOLARGO

BioLargo - A record-setting year

BioLargo reported record revenue of $1.86m for 2019, a 36% increase over 2018 and a record single quarter revenue of over $560,000 for Q4. Odor-no-More (ONM) had its best year to date with $1.46m in revenue ($832,000 gross profit). However, ONM fell short of its goal of breaking even for the year with a loss of $337,000 (albeit improved from the 2018 $433,000 loss) due to increased headcount for future growth. The company noted that in 2020 it will focus on increasing sales through improved dist...

04/02/20 April 2, 2020 2 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch